SRX Global Inc. to acquire CERo Therapeutics, Inc.

SRX Global Inc. has agreed to acquire CERo Therapeutics, Inc. in a strategic transaction within the healthcare sector. Both the buyer and the target are based in the United States. The deal was announced on 7 October 2026. The consideration for the acquisition consists of shares and a loan note. No specific monetary value or currency has been disclosed for this transaction. The completion date has not yet been reported. This arrangement represents a firm intention to proceed with the merger of the two entities. The structure involves an exchange of equity alongside debt instruments, rather than a simple cash payment. Details regarding the exact proportion of shares versus loan notes remain unreported. The transaction is currently in the firm intention stage, indicating that the parties have committed to the deal but have not yet finalized all closing conditions. Regulatory approvals and other standard closing requirements are likely pending. The healthcare sector context suggests a focus on therapeutic assets or capabilities. No further financial figures are available in the public record at this time. The transaction is subject to regulatory approval.